Refeyn Blog

Due to its precise genome editing capabilities, the prokaryotic CRISPR–Cas system has revolutionized molecular biology – and has potential applications in gene therapy and biotechnology [1]. Nonetheless, recent research has highlighted the need for more compact CRISPR-Cas complexes, which could be delivered to cellular systems more efficiently [2]

There is no better measure for the success of an analytical technology than its widespread adoption by the people who need the best data! As news of the capabilities and applications of mass photometry spreads, more and more scientists are choosing to use it. In fact, the number of scientific publications relying on mass photometry has grown by an average of 168% per year over the past 6 years. In August 2024, we hit a new milestone: 500 mass photometry papers! For a technology as young as mass photometry, that is truly remarkable.

Genetic Engineering & Biotechnology News (GEN) published a short article discussing how researchers at the UK Centre for Process Innovation (CPI) found mass photometry to be a helpful analytical technique for companies using adeno-associated viruses (AAV) as viral vectors in gene therapies.

An article authored by Laura Pala, one of our Product Marketing Managers, has recently been published by Eurolab magazine and also online at ScientistLive. It provides a useful overview of macro mass photometry and how it can help to speed up viral vector characterization, a key analytical step within the production pipeline for cell and gene therapies (CGT) and vaccines.

ABL, an Institut Mérieux Company, is a distinguished contract development and manufacturing organization (CDMO) providing GMP viral vectors from early stage to market.